Kabiven (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The mixture supplies a complete profile of essential amino acids directly into the bloodstream. These amino acids become substrates for hepatic and peripheral protein synthesis, replenish intracellular pools, support gluconeogenesis, and help maintain nitrogen balance, thereby aiding tissue repair and metabolic stability.

The dose of Kabiven is individualized by the prescribing clinician based on the patient’s weight, clinical condition, renal and hepatic function, and specific nutritional requirements. Dosing calculations follow established parenteral nutrition protocols and are adjusted according to laboratory monitoring.

The safety of Kabiven in pregnancy or lactation has not been definitively established. It should only be used if the potential benefits outweigh any potential risks, and the decision must be made by the treating physician in consultation with obstetric specialists.

To order Kabiven, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Kabiven offers a balanced blend of ten essential amino acids in a single intravenous formulation, meeting European regulatory standards. Compared with some alternatives that may contain additional non‑essential amino acids or different concentration ratios, Kabiven is designed for broad applicability in critical‑care nutrition while maintaining compatibility with standard IV fluids.

Kabiven must be stored at 2‑8 °C in a refrigerator. Keep the container in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Kabiven is administered intravenously, typically as a continuous infusion or via a controlled-rate pump, according to the prescribing clinician’s protocol. The solution is added to a compatible carrier fluid and infused through a central or peripheral venous line under aseptic conditions.

Serious risks include anaphylactic or severe hypersensitivity reactions, metabolic acidosis, hyperammonemia, and acute renal dysfunction. Prompt recognition of these events and immediate medical intervention are essential. Monitoring of vital signs, laboratory parameters and infusion site is recommended throughout therapy.

Kabiven should be avoided in patients with known hypersensitivity to any of its amino acid components, those with uncontrolled severe electrolyte disturbances, or individuals in whom intravenous amino acid administration is contraindicated due to specific metabolic disorders. Clinical judgment is required for each case.